FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200571522> ?p ?o ?g. }

• W3200571522 endingPage "113" @default.
• W3200571522 startingPage "103" @default.
• W3200571522 abstract "Direct (new) Oral Anticoagulants (DOACs) have emerged as a contemporary and promising option in the treatment of thromboses and VTE, while protecting the coagulation cascade against untoward bleeding events. They are used in the management and prophylaxis of Venous Thromboembolism (VTE) and other thrombotic diseases. The most prominent complication of these agents is bleeding. These agents have similar or lower rates of major intracranial hemorrhages, while they had a higher risk of major gastrointestinal bleeding when compared to warfarin. This manuscript is aimed to revise and update the literature findings to outline the side effects of DOACs in various clinical scenarios.A narrative review of currently published studies was performed. Online database searches were performed for clinical trials published before July 2021, on the efficacy and adverse effects attributed to the anticoagulant treatment, especially DOACs. A literature search via electronic databases was carried out, beginning with the usage of the agents in the Western Languages papers. The search terms initially included direct (new) oral anticoagulants, dabigatran, rivaroxaban, apixaban, edoxaban, idarucizumab, andexanet, prothrombin complex concentrates, and fresh frozen plasma. Papers were examined for methodological soundness before being included.Severe bleeding episodes require aggressive interventions for successful management. Therefore, bleeding should be evaluated in special regard to the location and rate of hemorrhage, and total volume of blood loss. Patient's age, weight and organ dysfunctions (e.g., kidney/liver failure or chronic respiratory diseases) directly affect the clinical course of overdose.Management recommendations for hemorrhage associated with DOAC use vary, depending on the class of the culprit agent (direct thrombin inhibitor vs. FXa inhibitor), the clinical status of the patient (mild/ moderate vs. severe/life-threatening), and capabilities of the institution. Specific reversal agents (i.e., idarucizumab and andexanet alfa) can be used if available, while prothrombin complex concentrates, fresh frozen plasma and/ or tranexamic acid can also be employed as nonspecific replacement agents in the management of DOAC-related bleeding diathesis." @default.
• W3200571522 created "2021-09-27" @default.
• W3200571522 creator A5013164986 @default.
• W3200571522 creator A5014755410 @default.
• W3200571522 creator A5036819168 @default.
• W3200571522 creator A5051420625 @default.
• W3200571522 creator A5054844060 @default.
• W3200571522 creator A5059042067 @default.
• W3200571522 creator A5059073654 @default.
• W3200571522 creator A5060155645 @default.
• W3200571522 creator A5086389518 @default.
• W3200571522 date "2022-07-01" @default.
• W3200571522 modified "2023-10-18" @default.
• W3200571522 title "Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal" @default.
• W3200571522 cites W1834574045 @default.
• W3200571522 cites W2046188252 @default.
• W3200571522 cites W2046562110 @default.
• W3200571522 cites W2068476516 @default.
• W3200571522 cites W2096246254 @default.
• W3200571522 cites W2098215452 @default.
• W3200571522 cites W2114962542 @default.
• W3200571522 cites W2117677020 @default.
• W3200571522 cites W2118476830 @default.
• W3200571522 cites W2119083251 @default.
• W3200571522 cites W2134427191 @default.
• W3200571522 cites W2148229222 @default.
• W3200571522 cites W2152623033 @default.
• W3200571522 cites W2163311091 @default.
• W3200571522 cites W2174386486 @default.
• W3200571522 cites W2196626069 @default.
• W3200571522 cites W2236830936 @default.
• W3200571522 cites W2291575320 @default.
• W3200571522 cites W2376415178 @default.
• W3200571522 cites W2492725532 @default.
• W3200571522 cites W2518797397 @default.
• W3200571522 cites W2518982463 @default.
• W3200571522 cites W2553572012 @default.
• W3200571522 cites W2557781513 @default.
• W3200571522 cites W2591915456 @default.
• W3200571522 cites W2617574242 @default.
• W3200571522 cites W2734827407 @default.
• W3200571522 cites W2749566272 @default.
• W3200571522 cites W2767737505 @default.
• W3200571522 cites W2769275060 @default.
• W3200571522 cites W2774819407 @default.
• W3200571522 cites W2781949590 @default.
• W3200571522 cites W2784115121 @default.
• W3200571522 cites W2791026080 @default.
• W3200571522 cites W2794249616 @default.
• W3200571522 cites W2802135046 @default.
• W3200571522 cites W2805499997 @default.
• W3200571522 cites W2914381505 @default.
• W3200571522 cites W2934397726 @default.
• W3200571522 cites W2939773760 @default.
• W3200571522 cites W2951544880 @default.
• W3200571522 cites W2957544571 @default.
• W3200571522 cites W2979558023 @default.
• W3200571522 cites W2980770901 @default.
• W3200571522 cites W2994664186 @default.
• W3200571522 cites W3001230339 @default.
• W3200571522 cites W3042321076 @default.
• W3200571522 cites W3124169281 @default.
• W3200571522 cites W3156964340 @default.
• W3200571522 cites W4226027124 @default.
• W3200571522 doi "https://doi.org/10.2174/1871525719666210914110750" @default.
• W3200571522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34521332" @default.
• W3200571522 hasPublicationYear "2022" @default.
• W3200571522 type Work @default.
• W3200571522 sameAs 3200571522 @default.
• W3200571522 citedByCount "5" @default.
• W3200571522 countsByYear W32005715222023 @default.
• W3200571522 crossrefType "journal-article" @default.
• W3200571522 hasAuthorship W3200571522A5013164986 @default.
• W3200571522 hasAuthorship W3200571522A5014755410 @default.
• W3200571522 hasAuthorship W3200571522A5036819168 @default.
• W3200571522 hasAuthorship W3200571522A5051420625 @default.
• W3200571522 hasAuthorship W3200571522A5054844060 @default.
• W3200571522 hasAuthorship W3200571522A5059042067 @default.
• W3200571522 hasAuthorship W3200571522A5059073654 @default.
• W3200571522 hasAuthorship W3200571522A5060155645 @default.
• W3200571522 hasAuthorship W3200571522A5086389518 @default.
• W3200571522 hasConcept C126322002 @default.
• W3200571522 hasConcept C141071460 @default.
• W3200571522 hasConcept C177713679 @default.
• W3200571522 hasConcept C197934379 @default.
• W3200571522 hasConcept C2776301958 @default.
• W3200571522 hasConcept C2776413415 @default.
• W3200571522 hasConcept C2776710957 @default.
• W3200571522 hasConcept C2778205648 @default.
• W3200571522 hasConcept C2778661090 @default.
• W3200571522 hasConcept C2778810321 @default.
• W3200571522 hasConcept C2779161974 @default.
• W3200571522 hasConcept C2780290652 @default.
• W3200571522 hasConcept C2780638905 @default.
• W3200571522 hasConcept C71924100 @default.
• W3200571522 hasConceptScore W3200571522C126322002 @default.
• W3200571522 hasConceptScore W3200571522C141071460 @default.
• W3200571522 hasConceptScore W3200571522C177713679 @default.

• next